| 货号 | 17189-500mg |
| 描述 | Erythromycin (Item No. 16486) is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.1 It is effective against a host of bacterial genera, including Streptococcus,Staphylococcus, and Haemophilus(MIC90s range from 0.015-2.0 mg/l).2 Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.3,4 Erythromycin lactobionate is a soluble salt of erythromycin that is typically used for intraperitoneal or intravenous injections.5,6 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Wilson, D.N. The A-Z of bacterial translation inhibitors. Crit. Rev. Biochem. Mol. Biol. 44(6), 393-433 (2009). 2.Kanatani, M.S., and Guglielmo, B.J. The new macrolides. Azithromycin and clarithromycin. Western J. Med. 160(1), 31-37 (1994). 3.Westphal, J.F. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin. British Journal of Clinical Pharmacology 50(4), 285-295 (2000). 4.Bibi, Z. Role of cytochrome P450 in drug interactions. Nutrition & Metabolism 5(27), 1-10 (2008). 5.Hirakata, Y.,Kaku, M.,Tomono, K., et al. Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice. Antimicrobial Agents and Chemotherapy 36(6), 1198-1203 (1992). 6.Austin, K.L.,Mather, L.E.,Philpot, C.R., et al. Intersubject and dose-related variability after intravenous administration of erythromycin. British Journal of Clinical Pharmacology 10(3), 273-279 (1980). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 计算分子量 | 1092.2 |
| 分子式 | C37H67NO13 • C12H22O12 |
| CAS号 | 3847-29-8 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |